Title21 Health Solutions, a leading provider of enterprise quality management systems and cell and gene therapy orchestration platforms, announced the acquisition of MyCellHub and its advanced manufacturing execution system (MES) platform, expanding digital solutions across the advanced therapies ecosystem.
Through the MyCellHub acquisition, Title21 enhances its ability to connect stakeholders in the advanced therapies field, enabling better data sharing, transparency, and faster therapy development. The addition of a MES platform positions Title21 as a single-source provider for hematopoietic cell transplant workflows, biotherapy manufacturing, integrated analytics, and quality management systems.
The MES technology delivers real-time production monitoring, digital batch record management, and embedded quality management tailored to healthcare, biotech, and cell therapy sectors.
“This strategic addition to our expanding product portfolio positions Title21 as the leader in arm-to-arm workflow, documentation, and compliance solutions for the developers, manufacturers, and clinical providers of life-saving biotherapies. It also expands our geographic coverage in North America and Australia to include Europe. We welcome the Belgium-based MyCellHub team to Title21 and look forward to adding them to our committed group of professionals advancing Healthcare IT in this important industry,” said Tony Pare, CEO of Title21.
Jacques Parlongue, CEO of MyCellHub, added, “We founded MyCellHub on the belief that GMP operations should be digital, efficient, and error-resistant. Title21 shares this vision. Their long history of innovation and commitment to patient safety aligns closely with our values and mission. As part of Title21, we will accelerate improvements, benefit from additional resources, and expand the tools available to support life-science organizations.”
The newly acquired MES complements Title21’s portfolio, which includes quality management systems, cell and gene therapy orchestration platforms, and advanced analytics offerings, all designed for advanced therapy medicinal product (ATMP) providers. The acquisition strengthens Title21’s position as a life sciences innovator, helping organizations reduce risk, improve operational efficiency, and bring life-saving therapies to market faster.